Kyung-Jae Lee1, Jeong Joon Yoo2, Kwang-Jun Oh3, Je-Hyun Yoo4, Kee Hyung Rhyu5, Kwang Woo Nam6, Dong-Hoon Suh7. 1. Department of Orthopaedic Surgery, Keimyung University Dongsan Medical Center, Daegu, South Korea. Electronic address: oslee@dsmc.or.kr. 2. Department of Orthopaedic Surgery, Seoul National University Hospital, Seoul, South Korea. Electronic address: jjyos@snu.ac.kr. 3. Department of Orthopaedic Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, South Korea. Electronic address: damioh@gmail.com. 4. Department of Orthopaedic Surgery, Hallym University Sacred Heart Hospital, Anyang, South Korea. Electronic address: oships@hallym.ac.kr. 5. Department of Orthopaedic Surgery, Kyung Hee University Hospital at Gangdong, Seoul, South Korea. Electronic address: khrhyu@empas.com. 6. Department of Orthopaedic Surgery, Jeju National University Hospital, Jeju, South Korea. Electronic address: kingkangu@gmail.com. 7. Department of Orthopaedic Surgery, Korea University Ansan Hospital, Ansan, South Korea. Electronic address: mayhap@hanmail.net.
Abstract
BACKGROUND: Management of atypical femoral fracture on bisphosphonate therapy still remains controversy and is reported high rate of complications. The aim of this study was to evaluate the outcome of intramedullary nailing in patients with atypical femoral fracture who took bisphosphonate more than one year through the multicenter retrospective study. METHODS: We gathered 75 atypical femoral fractures from seven institutions between 2009 and 2014. Among them 46 atypical femoral fractures which met the inclusion criteria was evaluated in this study. The average age was 70.1 years (53-80) and the average duration of bisphosphonate use was 5.1 years (1-15 years). Medical records and radiographs were reviewed to determine time to union, union rate, need for revision surgery, restoration of ambulatory function, and complications. RESULTS: Twenty-nine (63%) fractures healed within 6 months without complications. The average time to union except two non-union was 24.9 weeks (11-48 weeks). Two patients (4.3%) underwent revision surgery for non-union and there was no implant failure. Thirty-seven (80.4%) patients achieved their pre-fracture ambulatory function at the final follow up. CONCLUSIONS: Although the incidence of delayed bone healing is high in atypical femoral fracture on bisphosphonate therapy even treated with intramedullary nailing, the incidence of revision surgery and implant failure was relatively lower than those of extramedullary devices.
BACKGROUND: Management of atypical femoral fracture on bisphosphonate therapy still remains controversy and is reported high rate of complications. The aim of this study was to evaluate the outcome of intramedullary nailing in patients with atypical femoral fracture who took bisphosphonate more than one year through the multicenter retrospective study. METHODS: We gathered 75 atypical femoral fractures from seven institutions between 2009 and 2014. Among them 46 atypical femoral fractures which met the inclusion criteria was evaluated in this study. The average age was 70.1 years (53-80) and the average duration of bisphosphonate use was 5.1 years (1-15 years). Medical records and radiographs were reviewed to determine time to union, union rate, need for revision surgery, restoration of ambulatory function, and complications. RESULTS: Twenty-nine (63%) fractures healed within 6 months without complications. The average time to union except two non-union was 24.9 weeks (11-48 weeks). Two patients (4.3%) underwent revision surgery for non-union and there was no implant failure. Thirty-seven (80.4%) patients achieved their pre-fracture ambulatory function at the final follow up. CONCLUSIONS: Although the incidence of delayed bone healing is high in atypical femoral fracture on bisphosphonate therapy even treated with intramedullary nailing, the incidence of revision surgery and implant failure was relatively lower than those of extramedullary devices.
Authors: Michalis Panteli; James S H Vun; Robert M West; Anthony J Howard; Ippokratis Pountos; Peter V Giannoudis Journal: J Clin Med Date: 2021-11-29 Impact factor: 4.241
Authors: Adel Ebrahimpour; Mehrdad Sadighi; Amir Human Hoveidaei; Mohammadreza Chehrassan; Reza Minaei; Hamed Vahedi; Sm Javad Mortazavi Journal: Arch Bone Jt Surg Date: 2021-05
Authors: Denise M van de Laarschot; Malachi J McKenna; Bo Abrahamsen; Bente Langdahl; Martine Cohen-Solal; Núria Guañabens; Richard Eastell; Stuart H Ralston; M Carola Zillikens Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958